Andrew Tutt

87.4k total citations · 13 hit papers
161 papers, 24.5k citations indexed

About

Andrew Tutt is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Andrew Tutt has authored 161 papers receiving a total of 24.5k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 78 papers in Molecular Biology and 52 papers in Cancer Research. Recurrent topics in Andrew Tutt's work include PARP inhibition in cancer therapy (52 papers), DNA Repair Mechanisms (44 papers) and BRCA gene mutations in cancer (44 papers). Andrew Tutt is often cited by papers focused on PARP inhibition in cancer therapy (52 papers), DNA Repair Mechanisms (44 papers) and BRCA gene mutations in cancer (44 papers). Andrew Tutt collaborates with scholars based in United Kingdom, United States and Belgium. Andrew Tutt's co-authors include Alan Ashworth, Christopher J. Lord, Nicholas C. Turner, Alan Ashworth, Graeme C.M. Smith, Nuala McCabe, James Carmichael, J. S. Reis-Filho, Niall M.B. Martin and Stephen P. Jackson and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Andrew Tutt

153 papers receiving 24.0k citations

Hit Papers

Targeting the DNA repair defect in BRCA mutant cells as a... 2004 2026 2011 2018 2005 2009 2010 2010 2004 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    2005 4.8k citations Nuala McCabe, Christopher J. Lord et al. profile →
  2. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
    2009 2.7k citations Peter C.C. Fong, David S. Boss et al. profile →
  3. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    2010 1.7k citations James Carmichael, Andrew Tutt et al. profile →
  4. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    2010 1.3k citations Andrew Tutt, James Carmichael et al. profile →
  5. Hallmarks of 'BRCAness' in sporadic cancers
    2004 1.2k citations Nicholas C. Turner, Andrew Tutt et al. profile →
  6. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
    2006 977 citations Nuala McCabe, Nicholas C. Turner et al. Cancer Research profile →
  7. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
    2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →
  8. Triple negative tumours: a critical review
    2007 708 citations Andrew Tutt et al. profile →
  9. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
    2016 659 citations Andrew Tutt et al. profile →
  10. BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells
    2010 557 citations Felipe C. Geyer, Rachael Natrajan et al. profile →
  11. FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
    2010 544 citations Nicholas C. Turner, Alex Pearson et al. Cancer Research profile →
  12. A decade of clinical development of PARP inhibitors in perspective
    2019 495 citations Christopher J. Lord, Andrew Tutt et al. profile →
  13. Targeting folate receptor alpha for cancer treatment
    2016 348 citations James W. Opzoomer, Anita Grigoriadis et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Tutt United Kingdom 53 16.0k 14.6k 5.9k 5.2k 3.1k 161 24.5k
Christopher J. Lord United Kingdom 68 15.1k 0.9× 16.9k 1.2× 4.1k 0.7× 4.0k 0.8× 2.8k 0.9× 192 24.5k
Timothy A. Yap United States 52 8.6k 0.5× 9.0k 0.6× 3.3k 0.6× 1.9k 0.4× 3.8k 1.2× 353 16.3k
Bryan T. Hennessy Ireland 59 9.0k 0.6× 9.7k 0.7× 6.4k 1.1× 1.7k 0.3× 3.0k 1.0× 266 19.8k
Nicholas C. Turner United Kingdom 69 14.8k 0.9× 11.9k 0.8× 9.3k 1.6× 2.9k 0.6× 11.2k 3.6× 348 26.7k
Nicola J. Curtin United Kingdom 62 10.9k 0.7× 12.0k 0.8× 1.9k 0.3× 1.5k 0.3× 1.3k 0.4× 197 16.7k
David G. Huntsman Canada 86 6.8k 0.4× 10.9k 0.7× 5.6k 0.9× 2.7k 0.5× 4.0k 1.3× 350 24.7k
Nickolas Papadopoulos United States 65 11.7k 0.7× 13.1k 0.9× 10.6k 1.8× 2.7k 0.5× 3.4k 1.1× 164 28.1k
Geoffrey I. Shapiro United States 79 12.8k 0.8× 12.9k 0.9× 3.0k 0.5× 834 0.2× 7.8k 2.5× 500 23.0k
Graeme C.M. Smith United Kingdom 42 8.8k 0.5× 11.7k 0.8× 2.4k 0.4× 1.7k 0.3× 1.0k 0.3× 70 15.0k
Michael F. Press United States 73 20.2k 1.3× 9.6k 0.7× 8.7k 1.5× 3.8k 0.7× 4.8k 1.5× 226 30.5k

Countries citing papers authored by Andrew Tutt

Since Specialization
Citations

This map shows the geographic impact of Andrew Tutt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Tutt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Tutt more than expected).

Fields of papers citing papers by Andrew Tutt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Tutt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Tutt. The network helps show where Andrew Tutt may publish in the future.

Co-authorship network of co-authors of Andrew Tutt

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Tutt. A scholar is included among the top collaborators of Andrew Tutt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Tutt. Andrew Tutt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cutts, Ros, Sarah Hrebien, Aditi Gulati, et al.. (2024). Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling.. Journal of Clinical Oncology. 42(16_suppl). 1013–1013.
2.
Fitzpatrick, Amanda, Marjan Iravani, David Vicente, et al.. (2023). Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nature Communications. 14(1). 7408–7408. 9 indexed citations
3.
Krastev, Dragomir B., Shudong Li, Yilun Sun, et al.. (2022). The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nature Cell Biology. 24(1). 62–73. 92 indexed citations
4.
Fitzpatrick, Amanda, Marjan Iravani, Lucy Childs, et al.. (2021). Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis. Clinical Cancer Research. 28(6). 1180–1191. 44 indexed citations
5.
Pettitt, Stephen J., Jessica Frankum, Marco Punta, et al.. (2020). Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance. Cancer Discovery. 10(10). 1475–1488. 114 indexed citations
6.
Correia, Daniel V., Sofia Mensurado, Sandrina Nóbrega‐Pereira, et al.. (2018). Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells. Cancer Immunology Research. 6(4). 448–457. 31 indexed citations
7.
Muliaditan, Tamara, James W. Opzoomer, Jonathan Caron, et al.. (2018). Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. Clinical Cancer Research. 24(7). 1617–1628. 50 indexed citations
8.
Naidoo, Kuban D., Patty T. Wai, Sarah Maguire, et al.. (2018). Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer. Molecular Cancer Therapeutics. 17(1). 306–315. 54 indexed citations
9.
Grigoriadis, Anita, Patrycja Gazińska, Trupti Pai, et al.. (2018). Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node‐positive breast cancers. The Journal of Pathology Clinical Research. 4(1). 39–54. 20 indexed citations
10.
Koo, Chuay-Yeng, Caterina Giacomini, Yolanda Olmos, et al.. (2017). Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. Molecular Cancer Therapeutics. 16(11). 2410–2421. 40 indexed citations
11.
Lawler, Katherine, Efterpi Papouli, Cristina Naceur‐Lombardelli, et al.. (2017). Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. Breast Cancer Research. 19(1). 113–113. 4 indexed citations
12.
Lord, Christopher J., Andrew Tutt, & Alan Ashworth. (2014). Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors. Annual Review of Medicine. 66(1). 455–470. 344 indexed citations
13.
Marlow, Rebecca, Gabriella Honeth, Sara Lombardi, et al.. (2013). A Novel Model of Dormancy for Bone Metastatic Breast Cancer Cells. Cancer Research. 73(23). 6886–6899. 103 indexed citations
14.
Alduaij, Waleed, Andrei Ivanov, Jamie Honeychurch, et al.. (2011). Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 117(17). 4519–4529. 222 indexed citations
15.
Julien, Sylvain, Aleksandar Ívetic, Anita Grigoriadis, et al.. (2011). Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers. Cancer Research. 71(24). 7683–7693. 156 indexed citations
16.
Turner, Nicholas C., Alex Pearson, Rachel Sharpe, et al.. (2010). FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer Research. 70(5). 2085–2094. 544 indexed citations breakdown →
17.
Fong, Peter C.C., Timothy A. Yap, David S. Boss, et al.. (2010). Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology. 28(15). 2512–2519. 745 indexed citations breakdown →
18.
McCabe, Nuala, Nicholas C. Turner, Christopher J. Lord, et al.. (2006). Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition. Cancer Research. 66(16). 8109–8115. 977 indexed citations breakdown →
19.
Loi, Sherene, Christine Desmedt, Benjamin Haibe‐Kains, et al.. (2005). Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen. Breast Cancer Research and Treatment. 94. 1 indexed citations
20.
Bayne, Mike, M Zivanovic, Yong Du, et al.. (2004). Oral Presentations 1. British Journal of Cancer. 91(S1). S8–S9. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christopher J. Lord Breakdown of academic impact, for papers by Timothy A. Yap Breakdown of academic impact, for papers by Bryan T. Hennessy Breakdown of academic impact, for papers by Nicholas C. Turner Breakdown of academic impact, for papers by Nicola J. Curtin Breakdown of academic impact, for papers by David G. Huntsman Breakdown of academic impact, for papers by Nickolas Papadopoulos Breakdown of academic impact, for papers by Geoffrey I. Shapiro Breakdown of academic impact, for papers by Graeme C.M. Smith Breakdown of academic impact, for papers by Michael F. Press
Rankless by CCL
2026